Combining atezolizumab and chemotherapy for the first-line treatment of NSCLC, regardless of the PD-L1 expression, IMpower130, 131, and 132, had similar designs and outcomes (Table 2) [18,19,20]. Here, CD274 is linked to non-small cell lung carcinoma.